Insulin Aspart (Novolog) injectable bulk supplier for pharma manufacturers

Insulin Aspart (Novolog) Injectable U-100, U-200 Suppliers & Bulk Manufacturers

Available Forms: Vials/pens

Available Strengths: U-100, U-200

Reference Brands: Novolog, Fiasp(US &EU)

Category: Diabetes

Insulin Aspart (Novolog) is a rapid-acting insulin that mimics natural insulin release after meals. It quickly lowers blood sugar levels, providing flexible timing for meals. Its benefits include rapid onset, precise glucose control, reduced post-meal hyperglycemia, and improved convenience for insulin therapy in both type 1 and type 2 diabetes management.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description:

Insulin Aspart (Novolog) is a rapid-acting insulin approved in the EU and US for controlling blood glucose during meals. In the EU, Novo Nordisk’s Novolog and Fiasp are regulated by the EMA, with dossiers demonstrating safety, efficacy, and high manufacturing standards. In the US, the FDA has approved NovoLog and Fiasp based on comprehensive clinical data and biosimilarity studies, ensuring quality and consistency. Both regions require detailed regulatory dossiers and ongoing pharmacovigilance for safety monitoring. For expert assistance with regulatory dossiers and compliance, visit PharmaTradz, your trusted partner in pharmaceutical regulatory services.

Insulin Aspart (Novolog) Injectable — third party manufacturing & bulk supply

Insulin Aspart (Novolog) Injectable U-100, U-200 is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Insulin Aspart (Novolog) Injectable is supplied as Vials/pens — supplied in more than one dosage form, each with its own manufacturing economics, so the indicative MOQ is a minimum order value of USD 5,000 per product. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Insulin Aspart (Novolog) Injectable listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Insulin Aspart (Novolog) Injectable →

Back to Listing

Frequently Asked Questions

Insulin Aspart is used to improve blood sugar control in patients with diabetes mellitus, including both type 1 and type 2 diabetes. It helps regulate glucose levels by allowing sugar to enter cells where it is used for energy.

Insulin Aspart is a rapid-acting recombinant insulin analog produced using biotechnology. It is structurally modified from human insulin to allow faster absorption and quicker onset of action.

Common trade names include NovoLog, NovoRapid, Fiasp, and Trurapi.

The original insulin aspart products NovoLog and NovoRapid were developed and marketed by the pharmaceutical company Novo Nordisk, while other pharmaceutical companies manufacture biosimilar versions.

The generic name is Insulin Aspart.

Common brand names include NovoLog, NovoRapid, Fiasp, and Trurapi.

Insulin Aspart is manufactured in several countries including Denmark, the United States, and other regions by different pharmaceutical manufacturers.